Genomic rearrangements associated with prostate cancer and methods of using the same

US10711311B2 · kind B2 · utility

Assignee

• The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. · US

Inventors

• Shiv Srivastava · Potomac, US
• Albert Dobi · Columbia, US
• Gyorgy Petrovics · Bethesda, US
• Thomas Werner · Radebeul, DE
• Martin Seifert · West Simsbury, US
• Matthias Scherf · Gröbenzell, DE

Key dates

• Filing date: Dec 30, 2014
• Grant date: Jul 14, 2020
• Expiry date: Dec 30, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/156
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides genomic arrangements of the chromosome 3q13 region that are associated with prostate cancer, such as rearrangements between the ZBTB20 and LSAMP genes, including gene fusions between the ZBTB20 gene and the LSAMP gene and deletions spanning both genes. The ZBTB20/LSAMP genomic rearrangement serves as a biomarker for prostate cancer and can be used to stratify prostate cancer based on ethnicity or the severity or aggressiveness of prostate cancer and/or identify a patient for prostate cancer treatment. Another aspect involves discovering that deletions of the PTEN gene are observed predominately in prostate cancer from subjects of Caucasian descent. Also provided are kits for diagnosing and prognosing prostate cancer.